Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Small-Cap Opportunity Set Still Looks Attractive

BY | ETF Database
03/28/2024 | 347 VIEWS
Small-caps lagged last year. That’s because a small number of mega-cap growth stocks accounted for the bulk of the broader market’s returns. But there’s evidence the upside being generated in 2024 has more breadth than what was seen in 2023. That includes some signs of participation from small-cap stocks.For example, the Russell 2000 Index is high by 2.76% over the past month, and 4.45% year-to-date. Those gains could signal opportunity with ETFs such as the Invesco NASDAQ Future Gen 200 ETF (QQQS). As have many small-cap ETFs, QQQS entered 2024 with many of its holdings trading at steep discounts relative to large-cap equities. Even with recent strength among smaller stocks, the asset class remains attractive on valuation. “Valuations are compelling versus large caps, particularly on a price-to-earnings basis. The small-cap Russell 2000 index is trading at 65% of the large-cap Russell 1000 index, compared to a long-term average of just under 100%, so we are seeing a material relative undervaluation,” noted Jeff Dailey, head of U.S. equities at BNP Paribas.Catalysts Abound for QQQSAll valuation gaps between large- and small-cap benchmarks don’t need to be closed for the latter to rally. That’s because there are other potential tailwinds. Those include the possibility that the Federal Reserve will soon lower interest rates. “Easing cycles typically benefit small caps, and hiking cycles typically hurt [financial] markets; [markets are] currently calling for between two and four rate cuts this year. Macroeconomic data could push back the timing or [the number of] Fed cuts. Our base case is that we’re much closer to a Fed cut than a hike, and that’s good for small caps,” added Dailey. Specific to QQQS, another potential tailwind is a sustained rebound by biotech stocks. Healthcare equities, many of which are biotech, represent more than 53% of the QQQS portfolio. And 14.1% of those names are members of the S&P Biotechnology Select Industry Index. Though the sentiment is relevant to QQQS’ healthcare exposure, there are expectations that mergers and acquisitions could increase as 2024 progresses. And small-cap companies — healthcare and otherwise — make for prime takeover targets. “There are [signs pointing to] a more vibrant mergers & acquisitions environment. M&A has been particularly soft over the last couple of years due to tighter financial conditions and economic uncertainty. There is now a high probability that that will reverse, particularly with a healthy pipeline of deals that CEOs have lined up for strategic reasons. And M&As are always a nice tailwind for small caps,” concluded Dailey. For more news, information, and analysis, visit the ETF Education Channel.

More Commentary

This Emerging Markets ETFs Exclusionary Tactics Are Working
BY | ETF Database
04/30/2024 | 46 VIEWS
Top Performing Leveraged/Inverse ETFs: 04/28/2024
BY | ETF Database
04/30/2024 | 47 VIEWS
Position European Funds Ahead of Rate Shifts
BY | ETF Database
04/29/2024 | 26 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.

Copyright 1998–2024 FMR LLC. 
All rights reserved.